Enliven Therapeutics (ELVN) Insider Trading & Ownership $19.03 +0.29 (+1.54%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage25.90%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$8.67M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ELVN Insider Buying and Selling by Quarter Enliven Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/28/2025Benjamin HohlCFOSell3,250$20.46$66,495.00 7/21/2025Joseph P LyssikatosInsiderSell12,500$22.29$278,625.00 7/17/2025Samuel KintzCEOSell12,500$22.52$281,500.00 7/10/2025Benjamin HohlCFOSell1,000$22.66$22,660.00 7/7/2025Anish PatelCOOSell6,667$19.79$131,939.93 6/27/2025Benjamin HohlCFOSell3,250$20.91$67,957.50 6/20/2025Joseph P LyssikatosInsiderSell12,500$21.40$267,500.00 6/17/2025Samuel KintzCEOSell12,500$22.18$277,250.00 6/9/2025Anish PatelCOOSell6,667$20.34$135,606.78 6/3/2025Joseph P LyssikatosInsiderSell7,500$20.03$150,225.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/3/2025Samuel KintzCEOSell7,500$20.05$150,375.00 5/27/2025Benjamin HohlCFOSell3,250$16.18$52,585.00 5/19/2025Joseph P LyssikatosInsiderSell5,000$16.31$81,550.00 5/19/2025Samuel KintzCEOSell5,000$16.49$82,450.00 5/7/2025Anish PatelCOOSell6,667$18.39$122,606.13 5/1/2025Joseph P LyssikatosInsiderSell5,030$20.07$100,952.10 5/1/2025Samuel KintzCEOSell5,330$20.08$107,026.40 4/28/2025Benjamin HohlCFOSell3,250$18.69$60,742.50 4/21/2025Joseph P LyssikatosInsiderSell5,000$16.07$80,350.00 4/17/2025Samuel KintzCEOSell5,000$16.42$82,100.00 4/7/2025Anish PatelCOOSell6,667$18.04$120,272.68 3/27/2025Benjamin HohlCFOSell3,250$21.33$69,322.50 3/24/2025Benjamin HohlCFOSell1,000$22.50$22,500.00 3/19/2025Joseph P LyssikatosInsiderSell12,500$20.61$257,625.00 3/17/2025Samuel KintzCEOSell12,500$20.83$260,375.00 3/7/2025Anish PatelCOOSell6,667$21.44$142,940.48 2/27/2025Benjamin HohlCFOSell3,250$20.41$66,332.50 2/7/2025Anish PatelCOOSell6,667$21.93$146,207.31 2/5/2025Benjamin HohlCFOSell1,000$22.52$22,520.00 1/27/2025Benjamin HohlCFOSell3,250$21.59$70,167.50 1/7/2025Anish PatelCOOSell21,700$24.18$524,706.00 1/3/2025Benjamin HohlCFOSell1,000$25.04$25,040.00 12/30/2024Benjamin HohlCFOSell900$22.51$20,259.00 12/27/2024Benjamin HohlCFOSell3,350$22.15$74,202.50 11/27/2024Benjamin HohlCFOSell5,250$24.89$130,672.50 10/28/2024Benjamin HohlCFOSell6,250$28.56$178,500.00 10/18/2024Anish PatelCOOSell716$30.00$21,480.00 10/18/2024Benjamin HohlCFOSell814$30.00$24,420.00 10/18/2024Joseph P LyssikatosInsiderSell847$30.00$25,410.00 10/18/2024Richard A HeymanDirectorSell817$30.00$24,510.00 Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again.10/18/2024Samuel KintzCEOSell924$30.00$27,720.00 10/15/2024Richard A HeymanDirectorSell1,270$27.67$35,140.90 10/9/2024Joseph P LyssikatosInsiderSell37,878$28.16$1,066,644.48 10/9/2024Samuel KintzCEOSell16,710$28.15$470,386.50 10/8/2024Rahul D BallalDirectorSell10,420$28.17$293,531.40 10/7/2024Benjamin HohlCFOSell1,270$27.51$34,937.70 10/7/2024Joseph P LyssikatosInsiderSell2,707$27.61$74,740.27 10/7/2024Samuel KintzCEOSell2,730$27.50$75,075.00 10/4/2024Benjamin HohlCFOSell10,218$27.51$281,097.18 10/4/2024Joseph P LyssikatosInsiderSell7,522$27.51$206,930.22 10/4/2024Richard A HeymanDirectorSell2,825$27.51$77,715.75 10/4/2024Samuel KintzCEOSell12,206$27.51$335,787.06 10/1/2024Joseph P LyssikatosInsiderSell527$27.54$14,513.58 10/1/2024Richard A HeymanDirectorSell518$27.54$14,265.72 10/1/2024Samuel KintzCEOSell526$27.54$14,486.04 9/30/2024Benjamin HohlCFOSell2,000$25.33$50,660.00 9/27/2024Benjamin HohlCFOSell4,250$24.27$103,147.50 8/29/2024Joseph P LyssikatosInsiderSell12,000$22.49$269,880.00 8/27/2024Benjamin HohlCFOSell4,250$22.54$95,795.00 8/26/2024Samuel KintzCEOSell12,000$22.89$274,680.00 8/15/2024Richard A HeymanDirectorSell1,270$23.25$29,527.50 (Data available from 1/1/2013 forward) ELVN Insider Trading Activity - Frequently Asked Questions Who is on Enliven Therapeutics' Insider Roster? The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN. What percentage of Enliven Therapeutics stock is owned by insiders? 25.90% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings. Which Enliven Therapeutics insiders have been selling company stock? The following insiders have sold ELVN shares in the last 24 months: 5Am Partners Vi, Llc ($17,502,500.00), Anish Patel ($3,661,205.55), Benjamin Hohl ($2,724,454.54), Joseph P Lyssikatos ($3,280,754.09), Rahul D Ballal ($1,700,961.11), Richard A Heyman ($349,650.29), Rishi Gupta ($22,877,262.00), and Samuel Kintz ($5,789,474.18). How much insider selling is happening at Enliven Therapeutics? Insiders have sold a total of 3,056,004 Enliven Therapeutics shares in the last 24 months for a total of $59,741,023.44 sold. Enliven Therapeutics Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Compensation: $866.41kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder & Chief Scientific Officer Compensation: $632.67kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Compensation: $686.19kMr. Anish Patel Pharm.D. (Age 43)Co-Founder & COO Mr. Benjamin Hohl (Age 34)CFO & Head of Corporate Development Compensation: $488.5k8 recent tradesDr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development More Insider Trading Tools from MarketBeat Related Companies Zai Lab Insider Buying Akero Therapeutics Insider Buying Arcellx Insider Buying ACADIA Pharmaceuticals Insider Buying Viking Therapeutics Insider Buying Scholar Rock Insider Buying PTC Therapeutics Insider Buying SpringWorks Therapeutics Insider Buying MoonLake Immunotherapeutics Insider Buying Protagonist Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:ELVN) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
